263410-12-4

Basic information

• Product Name: tert-butyl 2-bromoethylmethylcarbamate
• Synonyms: tert-butyl 2-bromoethylmethylcarbamate;(2-Bromo-ethyl)-methyl-carbamic acid tert-butyl ester
• CAS NO: 263410-12-4
• Molecular Formula: C₈H₁₆BrNO₂
• Molecular Weight: 238.13
• Mol File: 263410-12-4.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 244.6±19.0 °C(Predicted)
• Appearance: /
• Density: 1.290±0.06 g/cm3(Predicted)
• PKA: -1.54±0.70(Predicted)
• CAS DataBase Reference: tert-butyl 2-bromoethylmethylcarbamate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 2-bromoethylmethylcarbamate(263410-12-4)
• EPA Substance Registry System: tert-butyl 2-bromoethylmethylcarbamate(263410-12-4)

Safety Data

• Hazardous Substances Data: 263410-12-4(Hazardous Substances Data)

Usage

Uses

tert-Butyl 2-Bromoethyl(methyl)carbamate is used in preparation of cyclic amino-pyrazinecarboxamide compound and uses thereof.

Upstream product

• 57561-39-4 methyl(2-hydroxyethyl)carbamic acid tert-butyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 1051929-53-3 tert-butyl 2-(4-((5-(2-methoxybenzylcarbamoyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)methyl)piperidin-1-yl)ethyl(methyl)carbamate 

Relevant articles and documents

Investigation of B,C-ring truncated deguelin derivatives as heat shock protein 90 (HSP90) inhibitors for use as anti-breast cancer agents

On the basis of deguelin, a series of the B,C-ring truncated surrogates with N-substituted amide linkers were investigated as HSP90 inhibitors. The structure activity relationship of the template was studied by incorporating various substitutions on the nitrogen of the amide linker and examining their HIF-1α inhibition. Among them, compound 57 showed potent HIF-1α inhibition and cytotoxicity in triple-negative breast cancer lines in a dose-dependent manner. Compound 57 downregulated expression and phosphorylation of major client proteins of HSP90 including AKT, ERK and STAT3, indicating that its antitumor activity was derived from the inhibition of HSP90 function. The molecular modeling of 57 demonstrated that 57 bound well to the C-terminal ATP-binding pocket in the open conformation of the hHSP90 homodimer with hydrogen bonding and pi-cation interactions. Overall, compound 57 is a potential antitumor agent for triple-negative breast cancer as a HSP90 C-terminal inhibitor.

CONJUGATES OF THE B-SUBUNIT OF SHIGA TOXIN FOR ANTICANCER THERAPIES

Conjugates or pharmaceutical compositions comprising conjugates of the B-subunit of Shiga toxin that are useful for cancer therapies are disclosed. More specifically, the pharmaceutical compositions comprise STxB conjugated to at least one antimitotic age

SHIGA TOXIN B-SUBUNIT/CHEMOTHERAPEUTICS CONJUGATES

The present invention relates to the use of a Shiga toxin B-subunit moiety as carrier for therapeutic agents, for example, anti-cancer agents such as anti-cancer agents that require intracellular uptake to exert their anti-cancer effects. In particular, the present invention provides conjugates comprising a Shiga toxin moiety covalently linked to an anti-cancer agent through a self-immolative spacer, and methods of using such conjugates to increase cellular uptake and/or specificity for cancer cells of the anti-cancer drug. Also provided are methods of treatment involving administration of such conjugates, and pharmaceutical compositions and kits useful for carrying out such methods of treatment.